Sino Lion Ventures Ltd has disclosed a reduction in its ownership percentage in Indaptus Therapeutics, Inc., according to a recent Schedule 13D/A filing with the SEC. The filing, dated October 22, 2026, indicates that Sino Lion now holds approximately 25.3% of Indaptus's common stock, down from a previous figure due to the issuance of new shares.
This development is significant as it reflects changes in shareholder dynamics at Indaptus, a company operating in the pharmaceutical preparations sector. The decrease in ownership comes as Indaptus prepares for a private placement, which may affect its capital structure and future financing strategies.
Background
Sino Lion Ventures Ltd, incorporated in the British Virgin Islands, is primarily an investment holding company. The firm has been involved in various transactions within the life sciences sector, including its recent dealings with Indaptus Therapeutics, Inc., which is based in New York and focuses on pharmaceutical preparations.
Indaptus Therapeutics has undergone several changes, including a name change from Intec Parent Inc. in April 2021. Recent filings indicate a series of amendments to ownership disclosures, with the latest being this Schedule 13D/A.
What the Filing Says
The filing states, "Sino Lion Ventures Limited beneficially owns 38,895,000 shares of the Issuer's Common Stock." This stake was acquired through a Securities Purchase Agreement dated March 19, 2026, and reflects a decrease in ownership percentage due to the issuance of additional shares by Indaptus.
Impact
This change in ownership may have implications for both Sino Lion Ventures and Indaptus Therapeutics. For Sino Lion, the reduction in stake could indicate a strategic shift or response to market conditions. For Indaptus, the influx of new shares through the private placement may affect its market perception and operational strategies.
What's Next
The filing does not say what happens next regarding Sino Lion's future plans or any additional actions related to its stake in Indaptus.